"Brain damage" is the phrase people reach for when memory and focus have not felt right after months or years on a benzodiazepine. It is not a diagnosis, and the research supports a more precise answer. Long-term use is linked to problems with memory, attention and the speed of thinking in some people. Most studies that followed people after they stopped found improvement, often over months, though not always back to the level of people who never took the drug. And a smaller group has withdrawal symptoms that last far longer than the taper itself.
Those are three different things, and a fourth possibility sits beside them: a symptom that was never the drug at all. Benzodiazepines work by strengthening GABA, the brain's main calming signal, which slows brain activity; how benzodiazepines act on the brain while they are being taken is its own subject. What follows is what happens after they stop, and how to tell which of these a person is dealing with.
Does Thinking Get Better Once Benzodiazepines Are Stopped?
In most studies, yes, partly and gradually. Thinking tests improve after withdrawal in many areas, but several studies still measured gaps at six months, and one small study found patients back at the level of healthy controls when they were retested about a year later. No study can say how fast one person will improve, or how far.
Key takeaways
- Long-term benzodiazepine use is linked to problems with memory, attention and the speed of thinking in some people.
- Most studies that followed people after stopping found improvement, often over months, though several still found gaps at six months and a full return cannot be promised.
- Protracted withdrawal is a separate problem: the FDA says its symptoms may last weeks to as long as 12 months, and some people report longer.
- A lingering symptom may be slow recovery, withdrawal or a condition that needs its own care, and an assessment is how those are told apart.
Long-Term Use Is Linked to Slower Thinking and Weaker Memory
The clearest evidence comes from studies that tested long-term users against people who did not take benzodiazepines. A meta-analysis of 13 such studies, covering people who had used the drugs for 1 to 34 years (9.9 on average), found the users more impaired in every area of thinking the studies measured. An updated meta-analysis of 19 studies, published in 2018, named the areas: working memory, processing speed, divided attention, recent memory, visual and spatial skills, and expressive language.
These findings describe people who took the drug for years. The FDA estimated that half of the people dispensed an oral benzodiazepine in 2018 received it for two months or longer, even though NIDA notes these medications are usually not prescribed for long-term use because of the risk of tolerance, dependence and addiction. The studies also measured function on tests, not injury. They show that long-term users, as a group, score lower; they do not show what has happened inside any one person's brain.
Studies Find Real Improvement After Stopping, With Gaps
A meta-analysis that pooled the follow-up studies found that long-term users regained function in many areas after withdrawal. It also found that they remained significantly below controls in most areas of thinking, at least in the first six months, and its authors concluded that some deficits may take longer than six months to recover or may not fully recover.
The individual studies vary widely. In a London study of 21 long-term users who completed inpatient withdrawal, there was no immediate improvement, and only modest recovery of some deficits by six months, still short of the comparison group. In a Swedish study, people tested about a year after a gradual taper had reached the level of healthy controls, which the authors read as evidence that the changes are at least partly reversible. In a trial of 192 older adults, most of whom had taken a sleeping medication for more than ten years, those who stopped did better on several thinking and coordination tasks at 24 or 52 weeks than those who kept taking it. The updated 2018 meta-analysis, which added newer studies, still found deficits in people who had stopped and stayed off.
Read together, the studies make improvement the usual finding and a full return something no one can promise. They are small, they tested people at different points, and none can give a timeline for one person.
Some Withdrawal Symptoms Last for Months, and a Few People Report Years
Separate from the thinking effects of the drug itself is protracted withdrawal. The FDA's 2020 safety communication on benzodiazepines describes a protracted withdrawal syndrome that persists beyond four to six weeks after the initial withdrawal, with symptoms that may last weeks to as long as 12 months. Its list includes cognitive impairment, alongside anxiety, depression, insomnia, tinnitus, tingling or crawling skin sensations, and muscle weakness, tremor or twitches. In the reports the FDA reviewed, symptoms lasted anywhere from weeks to years.
The largest source on long-lasting symptoms is an internet survey of 1,207 people recruited through benzodiazepine support groups and health sites. More than half of the respondents who had memory loss, distractedness or low energy said those symptoms lasted a year or longer, and some reported symptoms a year or more after they had stopped entirely. Seizures and hallucinations, by contrast, were among the shortest-lived symptoms. The survey has real limits: people chose to take part, there was no comparison group, and no one was independently diagnosed. A 2025 review of 46 studies that followed people at least four weeks after stopping found that stopping benefited many, while a subgroup had prolonged, sometimes disabling symptoms for months and years. How large that subgroup is could not be determined.
Why a Lingering Symptom Is Not Always the Drug
Benzodiazepines are prescribed for anxiety, panic and sleep problems, and those problems can return once the drug is gone. When the FDA reviewed reports of withdrawal, it named the difficulty of telling withdrawal symptoms apart from the return, or continuation, of the symptoms the drug had been treating. The evidence cuts both ways: in the internet survey, more than half of the people with prolonged anxiety and insomnia after stopping had not been prescribed the drug for that symptom, so for many of them it was new rather than an old condition returning.
For the reader, this changes the next step. Foggy thinking months after a taper could be the slow recovery the studies describe, protracted withdrawal, an anxiety or mood condition that needs its own care, or more than one of these at once. Sorting that out takes an assessment that looks at mental health alongside the drug history, which is a different thing from waiting it out.
Why Stopping Happens Slowly, on a Medical Plan
Whatever is behind a lingering symptom, the way off a benzodiazepine matters. The FDA's 2020 boxed warning states that stopping abruptly or reducing the dose too quickly can cause serious withdrawal reactions, including seizures, which can be life-threatening. It also says no standard taper schedule suits every patient, so the plan is built for the person, and it may be paused or slowed when withdrawal symptoms appear. Physical dependence is, in the FDA's words, the body's adaptation to repeated use of a drug; it is not a sign of weakness. The longer explanation of why tapering is medically supervised covers how dependence develops and what supervision involves.
The FDA lists these as the more severe withdrawal symptoms:
- seizures
- hallucinations, seeing or hearing things others do not
- delirium, with shaking, sweating and an irregular heartbeat
- catatonia, being unable to speak, with a rigid body
- mania or psychosis
- depression
- thoughts of suicide or of harming someone else
Where Guiding Road Fits Once Stabilization Is Done
Guiding Road is a residential treatment program for men in Phoenix, and benzodiazepines are among the substances it treats. It does not provide detox on site. When a man still taking a benzodiazepine needs detox first, Guiding Road coordinates that with medical partners, and residential care follows once he is stable. Care starts with an assessment that looks at co-occurring mental health conditions, such as anxiety and depression, alongside the drug history, which is where the question of what is causing a lingering symptom gets worked through.
More on treatment for benzodiazepine use is on the program page, and the admissions team is at (480) 588-2328.
Questions About Benzodiazepines and Long-Term Brain Health
Is there a test that shows whether benzodiazepines damaged my brain?
No single test answers that. Brain scans have not settled it: a CT study of 20 long-term users found no more brain shrinkage than in matched controls, while a large MRI study of older adults in the Netherlands linked current use to smaller hippocampal volume without a link to how much was taken. The studies of thinking and memory used neuropsychological tests, not scans, and found the differences there.
Do benzodiazepines cause dementia?
That is a separate question from the memory and attention effects described here, and the research on it is mixed. In the same Dutch study, which followed 5,443 older adults for an average of 11 years, overall benzodiazepine use was not associated with a higher risk of dementia, though higher cumulative use of anti-anxiety benzodiazepines showed a stronger association.
Is recovery different for older adults?
Older adults have the most direct trial evidence. Besides the gains on thinking and coordination tasks described above, the older adults in that trial who stopped their sleeping medication slept no worse, and reported no more withdrawal symptoms, than those who kept taking it, even though most had used it for more than ten years.
How common is withdrawal that lasts a year or more?
Nobody knows. The FDA described epidemiologic data on benzodiazepine dependence and withdrawal as scarce, and the 2025 review could not determine how common long-lasting symptoms are. The survey figures come from people who sought out support groups, so they describe that group well and the wider population of people who stop much less.
Does a short prescription carry the same risk to memory?
The thinking studies measured people who had taken benzodiazepines for years, an average of nearly ten in the first meta-analysis, so they say little about a course of a few weeks. That is a gap in the research rather than evidence that a short course leaves no effect: those studies were not designed to test it.
Sources
- U.S. Food and Drug Administration. (2020). FDA requiring Boxed Warning updated to improve safe use of benzodiazepine drug class.
- National Institute on Drug Abuse. Misuse of Prescription Drugs Research Report: What classes of prescription drugs are commonly misused?
- Barker, M. J., et al. (2004). Cognitive effects of long-term benzodiazepine use: a meta-analysis. CNS Drugs.
- Barker, M. J., et al. (2004). Persistence of cognitive effects after withdrawal from long-term benzodiazepine use: a meta-analysis. Archives of Clinical Neuropsychology.
- Crowe, S. F., and Stranks, E. K. (2018). The residual medium and long-term cognitive effects of benzodiazepine use: an updated meta-analysis. Archives of Clinical Neuropsychology.
- Tata, P. R., et al. (1994). Lack of cognitive recovery following withdrawal from long-term benzodiazepine use. Psychological Medicine.
- Tönne, U., et al. (1995). Neuropsychological changes during steady-state drug use, withdrawal and abstinence in primary benzodiazepine-dependent patients. Acta Psychiatrica Scandinavica.
- Curran, H. V., et al. (2003). Older adults and withdrawal from benzodiazepine hypnotics in general practice. Psychological Medicine.
- Ritvo, A. D., et al. (2023). Long-term consequences of benzodiazepine-induced neurological dysfunction: a survey. PLoS ONE.
- Huff, C., et al. (2023). Enduring neurological sequelae of benzodiazepine use: an internet survey. Therapeutic Advances in Psychopharmacology.
- Shade, K. N., et al. (2025). Long-term neurological consequences following benzodiazepine exposure: a scoping review. PLoS ONE.
- Busto, U. E., et al. (2000). Long-term benzodiazepine therapy does not result in brain abnormalities. Journal of Clinical Psychopharmacology.
- vom Hofe, I., et al. (2024). Benzodiazepine use in relation to long-term dementia risk and imaging markers of neurodegeneration: a population-based study. BMC Medicine.